CREB3L1 and breast cancer: Further, we have identified a small subset of luminal A breast cancers (7–24%) that are CREB3L1-deficient, suggesting that this subgroup of luminal A breast cancers is likely to be more metastatic and could be identified and treated with chemotherapy agents to improve the outcomes of these patients.